MX9304585A - Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. - Google Patents

Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.

Info

Publication number
MX9304585A
MX9304585A MX9304585A MX9304585A MX9304585A MX 9304585 A MX9304585 A MX 9304585A MX 9304585 A MX9304585 A MX 9304585A MX 9304585 A MX9304585 A MX 9304585A MX 9304585 A MX9304585 A MX 9304585A
Authority
MX
Mexico
Prior art keywords
dose
formulation
inhaler
aerosol
release
Prior art date
Application number
MX9304585A
Other languages
English (en)
Inventor
Anthony James Taylor
Philip John Neale
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929216382A external-priority patent/GB9216382D0/en
Priority claimed from GB929216381A external-priority patent/GB9216381D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX9304585A publication Critical patent/MX9304585A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

Esta invención se refiere a las nuevas formulaciones en aérosol para la administración de fármacos, en particular para la administración de un éster de beclometasona mediante inhalación. En particular, la invención proporciona nuevas formulaciones en aérosol que consiste esencialmente de (a) dipropionato de beclometasona en la forma de un solvato con 1,1,1,2-tetrafluoroetano (CF3CH2F) y uno o más propelentes de fluorocarburo o clorofluorocarburo que contiene hidrógeno, o (b) dipropionato de beclometasona anhidro y 1,1,1,2,3,3,3-heptafluoro-n-propano como el propelente.
MX9304585A 1992-07-31 1993-07-29 Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. MX9304585A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929216382A GB9216382D0 (en) 1992-07-31 1992-07-31 Medicaments
GB929216381A GB9216381D0 (en) 1992-07-31 1992-07-31 Medicaments

Publications (1)

Publication Number Publication Date
MX9304585A true MX9304585A (es) 1994-03-31

Family

ID=26301356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304585A MX9304585A (es) 1992-07-31 1993-07-29 Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.

Country Status (11)

Country Link
EP (2) EP0658101B1 (es)
JP (1) JPH07509475A (es)
CN (1) CN1052401C (es)
AT (2) ATE162709T1 (es)
AU (1) AU670616B2 (es)
DE (2) DE69333187T2 (es)
DK (1) DK0658101T3 (es)
ES (2) ES2112988T3 (es)
GR (1) GR3026185T3 (es)
MX (1) MX9304585A (es)
WO (1) WO1994003153A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
WO1994021386A2 (en) * 1993-03-25 1994-09-29 Research Corporation Technologies, Inc. Polymers useful in forming self-assembled bonded anisotropic ultrathin layers and their use
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
EE9700372A (et) * 1995-04-14 1998-06-15 Glaxo Wellcome Inc. Beklometasoondipropionaadi doseeriv inhalaator
EE03997B1 (et) * 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Albuterooli doseeriv inhalaator
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
CN100369608C (zh) * 2006-03-15 2008-02-20 修涞贵 一种治疗过敏性鼻炎的混悬液型喷雾剂及制备方法
EP2074421B1 (en) * 2006-10-12 2014-12-17 Koninklijke Philips N.V. Fast biosensor with reagent layer
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
IT1121513B (it) 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR880001237B1 (ko) 1984-07-25 1988-07-12 호비온 인터 리미티드 베클로메타손 17,21-디프로피오네이트의 용매화합물의 제조방법
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE69109284T2 (de) 1990-03-23 1995-08-24 Minnesota Mining & Mfg Verwendung von fluorierten löslichen tensiden zur herstellung von aerosolarzneimitteln mit dosierter abgabe.
BR9106595A (pt) * 1990-06-29 1993-04-20 Fisons Plc Composicao aerossol pressurizada
DK0553298T3 (da) * 1990-10-18 1995-04-18 Minnesota Mining & Mfg Aerosolformulering omfattende beclomethason-17,21-dipropionat
DE69231992T2 (de) * 1991-06-10 2001-12-13 Schering Corp Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
ES2269582T3 (es) * 1991-06-10 2007-04-01 Schering Corporation Formulaciones en aerosol sin clorofluorocarbonos.

Also Published As

Publication number Publication date
CN1088436A (zh) 1994-06-29
DE69333187D1 (de) 2003-10-09
EP0775484B1 (en) 2003-09-03
DK0658101T3 (da) 1998-09-21
CN1052401C (zh) 2000-05-17
JPH07509475A (ja) 1995-10-19
WO1994003153A1 (en) 1994-02-17
GR3026185T3 (en) 1998-05-29
AU670616B2 (en) 1996-07-25
EP0658101A1 (en) 1995-06-21
ATE248582T1 (de) 2003-09-15
ATE162709T1 (de) 1998-02-15
ES2112988T3 (es) 1998-04-16
EP0658101B1 (en) 1998-01-28
DE69333187T2 (de) 2004-07-15
EP0775484A1 (en) 1997-05-28
ES2206619T3 (es) 2004-05-16
AU4705093A (en) 1994-03-03
DE69316760D1 (de) 1998-03-05
DE69316760T2 (de) 1998-06-04

Similar Documents

Publication Publication Date Title
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
NO20065102L (no) Medikamenter
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
CA2125666A1 (en) Medicaments
ES2174970T3 (es) Mezcla propelente para formulacion de aerosol.
DK0656207T4 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
DE69005951T2 (de) Medikamente enthaltend Salmeterol und Fluticason.
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
FR2651678B1 (fr) Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees